Nurse Practitioner Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Denise Gomez

Nurse Practitioner Glendale, AZ Nurse Practitioner

NPI 1891279907 CMS profile 4567227

7200 W Bell Rd Unit 101, Glendale, AZ 85308

Open in the dashboard

General payments

$5,140

134 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Denise Gomez of Glendale, AZ is reported in the CMS Open Payments database as having received $5,140 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,495 40
2024 General $168 11
2023 General $181 10
2022 General $487 26
2021 General $1,767 45
2020 General $41 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Denise Gomez
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Denise Gomez were reported at $2,495. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Denise Gomez Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $41 $40 $16–$108 $114
2021 $1,767 $135 $40–$426 $132
2022 $487 $152 $48–$470 $149
2023 $181 $166 $54–$529 $160
2024 $168 $173 $55–$556 $164
2025 $2,495 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. BIOTRONIK NRO, Inc. $1,957 18 payments
  2. Biohaven Pharmaceuticals, Inc. $922 5 payments
  3. Boston Scientific Corporation $786 40 payments
  4. Nalu Medical, Inc. $381 10 payments
  5. Collegium Pharmaceutical, Inc. $261 17 payments
  6. AbbVie, Inc. $155 8 payments
  7. Hikma Pharmaceuticals USA $130 7 payments
  8. Scilex Pharmaceuticals Inc. $101 5 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $83 5 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $64 3 payments
  11. Other $301 16 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,050 124 payments
  2. Travel and Lodging $1,227 6 payments
  3. Consulting Fee $800 1 payment
  4. Education $63 3 payments
Products named General payments · program years 2020–2025
  1. Prospera $1,235 17 payments
  2. NURTEC ODT $986 8 payments
  3. Nalu Neurostimulation System $381 10 payments
  4. XTAMPZA $261 17 payments
  5. General - Pain Management $159 11 payments
  6. Kloxxado $130 7 payments
  7. UBRELVY $129 7 payments
  8. CLICK Dbs $92 1 payment
  9. Click Click_NMD $91 1 payment
  10. RELISTOR $83 5 payments
  11. Other $507 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

139

Median for Nurse Practitioner: 389

Drug cost

$19,458

Median for Nurse Practitioner: $21,885

Branded share of claims

28.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 19 $17,988
Albuterol Sulfate Hfa Albuterol Sulfate Brand 21 $417
Gabapentin Generic 19 $388
Atorvastatin Calcium Generic 25 $204
Metoprolol Succinate Generic 13 $147
Metformin Hcl Generic 13 $144
Pantoprazole Sodium Generic 11 $112
Lisinopril Generic 18 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$5,113

Medicare's payments for the services billed

Medicare patients

18

Average age 59

Services billed

71

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record